Group 1: Industry Overview - The IVD industry is experiencing an overall downturn, with the third quarter still in a consolidation phase [2] - External challenges include ongoing impacts from centralized procurement and adjustments to terminal charging policies [2][3] - Hospital operational issues are a significant factor leading to declines in both volume and price [2] Group 2: Company Performance - Revenue and profit have declined in the first three quarters of the year [2] - The adjustment of the domestic sales VAT from 3% to 13% has significantly impacted after-tax revenue growth [3] - The company is focusing on cash flow management, which has affected short-term revenue growth [3] Group 3: Domestic and International Business - Domestic business has faced pressure, while overseas performance has been relatively strong [3] - The U.S. subsidiary's toxicology business is recovering, and respiratory business is showing significant growth [3][6] - The company is expanding its international operations, with local supply chain and operational localization efforts underway [6][8] Group 4: Strategic Focus and Future Outlook - The company maintains confidence in future growth based on four core supports: continuous R&D investment, international market achievements, alignment with domestic policy opportunities, and exploration of emerging markets [8] - The focus for 2025 remains on terminal pure sales growth, cost control, and improving cash flow [3][8] - The company is optimistic about the potential for growth in the U.S. toxicology and respiratory markets [7]